Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tumour angiogenesis is a tightly regulated process involving cross-talk between tumour cells and the host tissue. The underlying mechanisms that regulate such interactions remain largely unknown. NG2 is a transmembrane proteoglycan whose presence on transformed cells has been demonstrated to increase proliferation in vitro and angiogenesis in vivo. To study the effects of NG2 during tumour growth and progression, we engineered an NG2 positive human
glioma
cell line (U251-NG2) from parental NG2 negative cells (U251-WT) and implanted both cell types stereotactically into immunodeficient nude rat brains. The tumours were longitudinally monitored in vivo using multispectral MRI employing two differently sized contrast agents (Gd-DTPA-
BMA
and Gadomer) to assess vascular leakiness, vasogenic oedema, tumour volumes and necrosis. Comparisons of Gd-DTPA-
BMA
and Gadomer revealed differences in their spatial distribution in the U251-NG2 and U251-WT tumours. The U251-NG2 tumours exhibited a higher leakiness of the larger molecular weight Gadomer and displayed a stronger vasogenic oedema (69.9 +/- 15.2, P = 0.018, compared to the controls (10.7 +/- 7.7). Moreover, immunohistochemistry and electron microscopy revealed that the U251-NG2 tumours had a higher microvascular density (11.81 +/- 0.54; P = 0.0010) compared to controls (5.76 +/- 0.87), with vessels that displayed larger gaps between the endothelial cells. Thus, tumour cells can regulate both the function and structure of the host-derived tumour vasculature through NG2 expression, suggesting a role for NG2 in the cross-talk between tumour-host compartments.
...
PMID:NG2 expression regulates vascular morphology and function in human brain tumours. 1625 23
This experiment aimed to compare the ionic (Gadodiamide, Gd-DTPA-
BMA
) and non-ionic (Gadopentetate dimeglumine, Gd-DTPA) gadolinium-based contrast agents (GBCA) in the quantitative evaluation of C6
glioma
with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). A C6
glioma
model was established in 12 Wistar rats, and magnetic resonance (MR) scans were performed six days after tumor implantation. Imaging was performed using a 3.0-T MR scanner with a 7-inch handmade circular coil. Pre-contrast T1 mapping and dynamic contrast-enhanced T1WI after a bolus injection (0.2 mL s
-1
) of GBCA at 0.4 mmol kg
-1
were performed. Each rat received two DCE-MRI scans, 24 h apart. The first and second scans were performed using Gd-DTPA-
BMA
and Gd-DTPA, respectively. Image data were processed using the Patlak model. Both K
trans
and V
p
maps were generated. Tumors were manually segmented on all 3D K
trans
and V
p
maps. Pixel counts and mean values were recorded for use in a paired t-test. Three radiologists independently performed the tumor segmentation and value calculation. The agreements from different observers were subjective to the intra-class correlation coefficient (ICC). Readers demonstrated that the pixel counts of tumors in K
trans
maps were higher with Gd-DTPA-
BMA
than with Gd-DTPA (P<0.001, all readers). Although the K
trans
values were higher with Gd-DTPA-
BMA
than with Gd-DTPA, there was no statistical significance (P>0.05, all readers). The pixel counts of tumors in V
p
maps, as well as V
p
values, showed no obvious difference between the two agents (P>0.05, all readers). Excellent interobserver measurement reproducibility and reliability were demonstrated in the ICC tests. The Gd-DTPA-
BMA
contrast agent had significantly higher pixel counts of
glioma
in the K
trans
maps, and an increased tendency for average K
trans
values, indicating that DCE-MRI with Gd-DTPA-
BMA
may be more suitable and sensitive for the evaluation of
glioma
.
...
PMID:Intra-individual comparison of different gadolinium-based contrast agents in the quantitative evaluation of C6 glioma with dynamic contrast-enhanced magnetic resonance imaging. 2807 11